Cellerant Therapeutics is a clinical-stage company developing innovative cell- and antibody-based immunotherapies for hematologic malignancies and other blood-related disorders. Cellerant’s Romyelocel-L is a universal cell therapy that does not require HLA matching intended to prevent bacterial and fungal infections during neutropenia.

It was